Cipla To Make, Sell US’s Eli Lilly’s Baricitinib Drug For Covid Treatment

0

In November, the US Food and Drug Administration initially gave Eli Lilly an emergency use approval for baricitinib in combination with remdesivir to treat COVID-19 patients.

Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment


Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly’s arthritis drug baricitinib for the treatment of COVID-19 patients.

The agreement comes at a time when India is struggling with a catastrophic second wave of the pandemic, leading to an acute shortage of coronavirus medicines such as remdesivir and tocilizumab.

Baricitinib has been given restricted emergency use approval by India’s drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Cipla said in a filing to stock exchanges.

In November, the U.S. Food and Drug Administration initially gave Eli Lilly an emergency use approval for baricitinib in combination with remdesivir to treat COVID-19 patients.

Cipla’s deal with Lilly expands the Indian drugmaker’s portfolio of COVID-19 drugs. Aside from remdesivir and tocilizumab, the company also offers antiviral drug favipiravir, used to treat patients with moderate to mild COVID-19.

Last week, Cipla said it would be the local distribution partner for a COVID-19 antibody drug cocktail developed by Roche and Regeneron, after the therapy got emergency use approval from India’s drug regulator.

India has posted more than 400,000 daily coronavirus cases for the past four days, and its total infections have reached nearly 22.30 million, the second highest number of cases in the world after the United States.

(Except for the headline, this story has not been edited by our staff and is published from a syndicated feed.)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

All the data shown above will be stored by www.rajpostexam.com on https://www.rajpostexam.com/. At any point of time, you can contact us and select the data you wish to anonymise or delete so it cannot be linked to your email address any longer. When your data is anonymised or deleted, you will receive an email confirmation. We also use cookies and/or similar technologies to analyse customer behaviour, administer the website, track users' movements, and to collect information about users. This is done in order to personalise and enhance your experience with us. Click here to read our Cookie Policy.